Clinical Trial Update: CD19-targeted CAR T Cells for Relapsed and Refractory (R/R) Large B-cell Lymphoma [Phase 2]

View source ↗

Summary

This document provides an update on a Phase 2 clinical trial of CD19-targeted CAR T cells for relapsed or refractory large B-cell lymphoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma
• Non-hodgkin Lymphoma

Drugs mentioned

• CD19-targeted CAR T cells

Snippet

Sponsor: Shanghai Ming Ju Biotechnology Co., Ltd. | Conditions: Lymphoma, Non-Hodgkin, Diffuse Large B Cell Lymphoma | Phase 2 | Status: UNKNOWN